Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice

被引：0
|
作者：
Abitbol, Alexander
Brown, Ruth E.
Jiandani, Dishay
Aronson, Ronnie
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1032-P
引用
收藏
页码：A272 / A272
页数：1
相关论文
共 50 条
  • [1] REAL-WORLD EVIDENCE DEMONSTRATES COMPARABLE CLINICAL OUTCOMES OF SWITCHING FROM INSULIN GLARGINE 100 U/ML TO INSULIN GLARGINE 300 U/ML VS INSULIN DEGLUDEC IN T2D PATIENTS
    Blonde, L.
    Zhou, F. L.
    Bosnyak, Z.
    Westerbacka, J.
    Gupta, V. E.
    Sharma, R. K.
    Bailey, T. S.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 : A137 - A138
  • [2] Improved real-world outcomes for type 2 diabetes patients on basal-bolus insulin therapy switching to insulin glargine 300 U/ml vs. insulin glargine 100 U/ml and insulin Detemir
    Wu, Jasmanda
    Bailey, Timothy S.
    Bosnyak, Zsolt
    Westerbacka, Jukka
    Gupta, Rishab A.
    Menon, Arjun A.
    Nicholls, Charlie
    Blonde, Lawrence
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 416 - 417
  • [3] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching from Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    DIABETES, 2018, 67
  • [4] Improved Glycemic Control with Insulin Glargine 300 U/mL vs. Glargine 100 U/mL in Type 1 Diabetes
    Paola, Lucidi
    Cioli, Patrizia
    Candeloro, Paola
    Andreoli, Anna Marinelli
    Bolli, Geremia B.
    Fanelli, Carmine G.
    Porcellati, Francesca
    DIABETES, 2020, 69
  • [5] Real-World Health Outcomes of Insulin Glargine 300 U/mL (Gla-300) vs. Insulin Glargine 100 U/mL (Gla-100) in Patients with Type 1 (T1D) and Type 2 Diabetes (T2D) in the Canadian LMC Diabetes Patient Registry-The REALITY Study
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Sauriol, Luc
    Aronson, Ronnie
    DIABETES, 2018, 67
  • [6] Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study
    Abitbol, Alexander
    Brown, Ruth E.
    Jiandani, Dishay
    Sauriol, Luc
    Aronson, Ronnie
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (07) : 504 - +
  • [7] Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
    Steinstraesser, A.
    Schmidt, R.
    Bergmann, K.
    Dahmen, R.
    Becker, R. H. A.
    DIABETES OBESITY & METABOLISM, 2014, 16 (09): : 873 - 876
  • [8] Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats
    Saini, N. K.
    Wasik, B.
    Pires, J.
    Leale, D. M.
    Quach, N.
    Culp, W. T. N.
    Samms, R. J.
    Johnson, A. E.
    Owens, J. G.
    Gilor, C.
    DOMESTIC ANIMAL ENDOCRINOLOGY, 2021, 75
  • [9] Real-World Clinical Outcomes of Type 2 Diabetes (T2D) Patients Switching From Insulin Glargine 100 U/mL (Gla-100) or Insulin Detemir (IDet) to Insulin Glargine 300 U/mL (Gla-300) or Insulin Degludec (IDeg)-DELIVER D plus Subgroup Analyses
    Sullivan, Sean D.
    Bailey, Timothy S.
    Roussel, Ronan
    Zhou, Fang L.
    Bosnyak, Zsolt
    Preblick, Ron
    Westerbacka, Jukka
    Gupta, Rishab
    Blonde, Lawrence
    DIABETES, 2018, 67
  • [10] THE REAL-WORLD DOSE DIFFERENCES OF INSULIN GLARGINE 300 U/ML IN FINLAND
    Koski, L.
    Hahl, J.
    Kaye, S.
    Pousar, K.
    VALUE IN HEALTH, 2019, 22 : S596 - S596
12345